Clinical trial · Interventional
Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer
An Evaluation of the Effect of Androgen Ablation on Bone Resorption in Prostate Cancer Patients
NCT00003903CI-TRIAL-00012401completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Assessing the effect of androgen suppression on bone loss in prostate cancer patients may improve the ability to plan treatment, may decrease the risk of fractures and bony pain, and may help patients live more comfortably. PURPOSE: Clinical trial to determine the effect of androgen suppression on bone loss in patients who have prostate cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Osteoporosis | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| management of therapy complications | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed prostate cancer * Stratum 1 (androgen ablation therapy): * Bone metastases * Prior orchiectomy allowed * Prior or concurrent leuprolide and/or goserelin therapy allowed * Stratum 2 (androgen ablation therapy): * No bone metastases * Prior orchiectomy allowed * Prior or concurrent leuprolide and/or goserelin therapy allowed * Stratum 3 (no androgen ablation therapy): * No metastatic disease * Prior flutamide or bicalutamide therapy allowed PATIENT CHARACTERISTICS: Age: * Not specified Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Calcium normal Hepatic: * Not specified Renal: * Not specified PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * See Disease Characteristics Endocrine therapy: * See Disease Characteristics * No concurrent high dose steroids Radiotherapy: * Prior radiotherapy allowed Surgery: * See Disease Characteristics * Prior radical prostatectomy allowed Other: * No concurrent bisphosphonates
References
Publications (0)
Data not yet available
No reference posted for this study.